The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Lushnikova P.A.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia;
Tomsk Regional Oncology Center, Tomsk, Russia

Startseva Zh.A.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia

Polyakov A.A.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia;
Tomsk Regional Oncology Center, Tomsk, Russia

Velikaya V.V.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia

Pyzhova I.B.

Tomsk Regional Oncology Center, Tomsk, Russia

Taletsky A.V.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia;
Tomsk Regional Oncology Center, Tomsk, Russia

Gribova O.V.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia

The contribution of radiation therapy in the treatment of endometrial cancer

Authors:

Lushnikova P.A., Startseva Zh.A., Polyakov A.A., Velikaya V.V., Pyzhova I.B., Taletsky A.V., Gribova O.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2026;15(3): 86‑90

DOI: 10.17116/onkolog20261503186

Read: 262 times

Contact the author
Table of contents

THE CONTRIBUTION OF RADIATION THERAPY IN THE TREATMENT OF ENDOMETRIAL CANCER
THE CONTRIBUTION OF RADIATION THERAPY IN THE TREATMENT OF ENDOMETRIAL CANCER

To cite this article:

Lushnikova PA, Startseva ZhA, Polyakov AA, Velikaya VV, Pyzhova IB, Taletsky AV, Gribova OV. The contribution of radiation therapy in the treatment of endometrial cancer. P.A. Herzen Journal of Oncology. 2026;15(3):86‑90. (In Russ.)
https://doi.org/10.17116/onkolog20261503186

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Evaluation of the skeletal muscle index in predicting toxic complications of anti­tumor drug therapy in patients with gastric cancer. P.A. Herzen Journal of Onco­logy. 2025;(4):29-36
Small cell carcinoma of the paro­tid gland. P.A. Herzen Journal of Onco­logy. 2025;(4):69-74
Resu­lts of testing an antioxidant gel film for the prevention and treatment of palmar-plantar syndrome in cancer patients. P.A. Herzen Journal of Onco­logy. 2025;(5):59-63
Proton therapy of skull base chordoma. P.A. Herzen Journal of Onco­logy. 2025;(5):64-67
Use of gona­dotropic releasing hormone agonists in hype­rplastic syndrome in gyne­cology. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):51-58
Prevention and treatment of dermal toxi­city in children receiving anti-tumor radiation. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):470-480
Characteristics of the immune microenvironment of endo­metrial cancer depe­nding on the MMR status of the tumor. Russian Journal of Archive of Pathology. 2025;(5):11-19
Predictors of arrhythmia and adve­rse outcomes in cancer patients during anti­tumor treatment. Russian Journal of Preventive Medi­cine. 2025;(11):86-93
Prevention and basic therapy of skin toxic reactions in children receiving anti-cancer drug therapy. Part 1. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):828-836
Hypo­fractionated irra­diation for intracranial meni­ngiomas. Burdenko's Journal of Neurosurgery. 2025;(6-2):21-28
Abstract:

Endometrial cancer (EC) is a fairly common disease in the female population today. The main treatment is surgery. However, in some cases, patients need combined treatment: surgery in combination with a course of remote radiation therapy, brachytherapy or courses of drug treatment. Adjuvant treatment in these cases is prescribed in the presence of risk factors for disease progression and is necessary to increase overall and disease-free survival in patients with EC. For the correct prescription of adjuvant therapy, radiotherapists should know the risk factors for the progression of endometrial cancer after surgery and follow generally accepted clinical guidelines in the treatment of this pathology. It is unacceptable to currently prescribe adjuvant treatment unreasonably, and at the same time, risk factors for progression cannot be ignored. This article demonstrates possible risk factors for progression in patients with ER after surgical treatment and shows the adjuvant treatment regimens that are necessary for this group of patients.

Keywords:

endometrial cancer
uterine cancer
radiation therapy
chemotherapy
external beam radiation therapy
brachytherapy
progression factors

Authors:

Lushnikova P.A.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia;
Tomsk Regional Oncology Center, Tomsk, Russia

Startseva Zh.A.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia

Polyakov A.A.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia;
Tomsk Regional Oncology Center, Tomsk, Russia

Velikaya V.V.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia

Pyzhova I.B.

Tomsk Regional Oncology Center, Tomsk, Russia

Taletsky A.V.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia;
Tomsk Regional Oncology Center, Tomsk, Russia

Gribova O.V.

Cancer Research Institute — Tomsk National Research Medical Center, Tomsk, Russia

Received:

11.07.2025

Accepted:

22.08.2025

Close metadata

References:

  1. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Moscow: P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia; 2024. 276p. (In Russ.).
  2. Uterine cancer and uterine sarcomas: Clinical recommendations of the Ministry of Health of the Russian Federation. 2024. (in Russian). https://cr.minzdrav.gov.ru/preview-cr/554_3]
  3. Abu-Rustum NR, Campos SM , Amarnath S, Arend R, Barber E, Bradley K. et al. Uterine Neoplasms, NCCN Guidelines Version 3.2025 
  4. Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, Ledermann J et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma- update 2025. Lancet Oncol. 2025;26(8):423-435.  https://doi.org/10.1016/S1470-2045(25)00560-1
  5. Brower JV, Bregar AJ, Klopp AH. Path to Precision: Refining Radiation Therapy Guidelines for Early Stage Endometrial Cancer Through Incorporation of Primary Tumor Size, Lower Uterine Segment Invasion, and Molecular Markers. Pract Radiat Oncol. 2024;14(2):154-160.  https://doi.org/10.1016/j.prro.2023.11.009
  6. Leon-Castillo A, Horeweg N, Peters EEM, Rutten T, Ter Haar N et al. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. Gynecol Oncol. 2022;164(3):577-586.  https://doi.org/10.1016/j.ygyno.2022.01.007
  7. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novak Z, Black D et al. RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145-2158. https://doi.org/10.1056/NEJMoa2216334
  8. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388(23):2159-2170. https://doi.org/10.1056/NEJMoa2302312
  9. RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer. 2023 ;33(1):109-117.  https://doi.org/10.1136/ijgc-2022-004039
  10. Payanidi MV, Kiseleva MA, Filina TI. Features of preserving fertility in patients with endometrial cancer according to the new European guidelines. Onkoginekologiya 2024;3: 25-34. (In Russ.) https://osors.ru/oncogynecology/JurText/j2024_3/03_24_25.pdf
  11. Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014;4(3):137-144.  https://doi.org/10.1016/j.prro.2014.01.003
  12. Sorbe B, Nordstrom B, Maenpaa J, Kuhelj J, Kuhelj D, Okkan S et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009;19(5):873-8.  https://doi.org/10.1111/IGC.0b013e3181a6c9df
  13. Serkies K, Baczkowska-Waliszewska Z. Adjuvant vaginal cuff brachytherapy in surgically treated endometrial carcinoma patients — in view of the recent evidence. J Contemp Brachytherapy. 2021;13(2):221-230.  https://doi.org/10.5114/jcb.2021.105291
  14. Lancellotta V, De Felice F, Vicenzi L, Antonacci A, Cerboneschi V, Costantini S et al.The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. J Contemp Brachytherapy. 2020;12(1):61-66.  https://doi.org/10.5114/jcb.2020.92698
  15. Qu XM, Velker VM, Leung E, Kwon JS, Elshaikh MA, Kong I et al. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis. Gynecol Oncol. 2018 ;149(2):283-290.  https://doi.org/10.1016/j.ygyno.2018.03.002
  16. Nechushkina VM, Kolomiets LA, Kravets OA. Practical recommendations for the medical treatment of uterine body cancer and uterine sarcomas. RUSSCO Practical Recommendations. Malignant Tumors. Part 1.2. 2024; 14( N3S2):165-188. (In Russ.).
  17. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD et al. Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744-51.  https://doi.org/10.1016/j.ygyno.2003.11.048
  18. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000 ;355(9213):1404-11.  https://doi.org/10.1016/s0140-6736(00)02139-5
  19. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC et al. PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010; 375(9717):816-23.  https://doi.org/10.1016/S0140-6736(09)62163-2
  20. Harkenrider MM, Abu-Rustum N, Albuquerque K, Bradfield L, Bradley K, Dolinar E et al. Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2023;13(1):41-65.  https://doi.org/10.1016/j.prro.2022.09.002
  21. Harkenrider MM, Martin B, Nieto K, Small C, Aref I, Bergman D et al. Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma. Int J Radiat Oncol Biol Phys. 2018; 101(5):1069-1077. https://doi.org/10.1016/j.ijrobp.2018.04.049
  22. Zhao F, Tan P, Wang C, Ji X, Chen A. Effect of adjuvant therapy on the prognosis in stage I/II uterine carcinosarcoma: A meta-analysis. J Obstet Gynaecol Res. 2021;47(7):2473-2480. https://doi.org/10.1111/jog.14800
  23. Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol. 2019;37(21):1810-1818. https://doi.org/10.1200/JCO.18.01575
  24. Ronsini C, Napolitano S, Iavarone I, Fumiento P, Vastarella MG, Reino A et al. The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis. J Clin Med. 2024 5;13(5):1496. https://doi.org/10.3390/jcm13051496
  25. Ballester M, Bendifallah S, Darai E. Nouvelles recommandations EMSO, ESGO, ESTRO sur la prise en charge des cancers de l’endomètre [European guidelines (ESMO-ESGO-ESTRO consensus conference) for the management of endometrial cancer]. Bull Cancer. 2017;104(12):1032-1038. https://doi.org/10.1016/j.bulcan.2017.10.006
  26. Ferrero A, Fuso L, Cipullo I, Danese R, Rossi A, Gribaudo S et al. The «Sandwich» Schedule: A Well-Tolerated Adjuvant Treatment Both in Intermediate-High- and High-Risk Endometrial Cancer. Curr Oncol. 2022;29(12):9224-9234. https://doi.org/10.3390/curroncol29120722
  27. Awada A, Gwacham N , Recio F, Kuhn T.Analysis of “sandwich” chemo-radiation therapy for stage IIIC endometrial cancer. Gynecologic Oncology.2023; 176.  https://doi.org/10.1016/j.ygyno.2023.06.132
  28. Raspagliesi F, Bogani G, Pinelli C, Casarin J, Cerrotta AM, Delle Curti CT et al. Patterns of failure after adjuvant «sandwich» chemo-radio-chemotherapy in locally advanced (stage III-IVA) endometrial cancer. J Cancer Res Clin Oncol. 2021;147(3):813-820.  https://doi.org/10.1007/s00432-020-03339-y
  29. Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019;380(24):2317-2326. https://doi.org/10.1056/NEJMoa1813181
  30. Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95(3):266-71.  https://doi.org/10.1038/sj.bjc.6603279
  31. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C et al. PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273-1285. https://doi.org/10.1016/S1470-2045(19)30395-X
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.